Najjar YG. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J ImmunoTher Cancer 2021;9:e002820. doi: 10.1136/jitc-2021-002820.

This article has been corrected since it was first published. A sentence in the second paragraph of this article read, "However, recently announced disappointing phase III results for these agents combined with an ICI in the front-line (T-VEC with pembrolizumab halted by the data safety monitoring committing (sic) for futility) and PD-1-refractory settings (tilsotolimod with ipilimumab failed to meet the primary endpoint of ORR, and the study was halted, given that the combination was unlikely to impact OS), respectively, mean that the search for more effective and well-tolerated therapies continues and that even in this period of unprecedented successes, the difficulty to move agents successfully from phase II to phase III remains an issue for the field.”

While it is true that the T-VEC plus pembrolizumab MASTERKEY-265 phase three study was halted for futility, the highlighted wording above implies that the study was stopped due to safety concern, which was not the case. The phase 3 MASTERKEY-265 study was recommended to be halted by the Data Monitoring Committee (not the safety monitoring committee) due to futility on efficacy after an interim analysis. No new safety signals were observed. This sentence has now been corrected accordingly.